Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Moxonidine 0.3 mg Tablet
Therapeutic Category
Hypertension/ Blood Pressure, Cardiology, Cardiovascular
Dosage Form
Tablet
Packaging Type
Alu Alu
Packaging
10*10
Price
₹114/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Moxonidine 0.3 mg Tablet is a centrally acting antihypertensive agent belonging to the imidazoline receptor agonist class. It lowers blood pressure by selectively stimulating imidazoline I₁ receptors in the brainstem, which reduces sympathetic nerve activity and leads to decreased vascular resistance and heart rate. Compared to older central antihypertensives like clonidine, Moxonidine offers effective blood pressure control with fewer sedative and dry mouth side effects due to its higher selectivity. The 0.3 mg strength is typically used in patients requiring a higher dose after being stabilized on lower strengths (such as 0.2 mg). Moxonidine is especially beneficial in patients with metabolic syndrome or type 2 diabetes, as it has minimal effect on lipid and glucose metabolism. It provides 24-hour blood pressure control with once-daily dosing and can be used alone or in combination with other antihypertensive medications.
Common side effects include dizziness, headache, dry mouth, fatigue, and drowsiness, especially during initial treatment. Some patients may experience sleep disturbances, gastrointestinal discomfort, or mild hypotension. Rare but serious adverse effects include bradycardia, severe hypotension, and allergic reactions. Side effects often improve after a few days of continuous therapy as the body adjusts to the medication.
Moxonidine 0.3 mg Tablet is indicated for the treatment of essential hypertension in adults, particularly in patients who are intolerant or unresponsive to conventional first-line antihypertensives or those with metabolic risk factors.
Moxonidine 0.3 mg should be taken only under medical supervision. It is not recommended in patients with severe bradycardia, sick sinus syndrome, heart block, or advanced heart failure unless prescribed by a specialist. Sudden discontinuation should be avoided as it may cause a rebound rise in blood pressure; tapering the dose gradually is advised. Caution should be exercised in patients with kidney impairment, and dose adjustment may be required. The medication is not recommended during pregnancy or breastfeeding unless deemed essential by a physician. Alcohol intake should be minimized as it can increase drowsiness and enhance the blood pressure-lowering effect. Regular blood pressure monitoring is essential to ensure safe and effective treatment.
Store Moxonidine 0.3 mg Tablet in a cool, dry place below 30°C, away from moisture and direct sunlight. Keep the tablets in their original packaging and out of the reach of children. Do not use the medication beyond the expiry date printed on the strip.
Composition : Aspirin 75mg + Rosuvastatin 10mg + Clopidogrel 75mg Tablet
Composition : Aspirin 75mg + Rosuvastatin 20mg + Clopidogrel 150mg Tablet
Composition : Rosuvastatin 10 mg + Aspirin 75 mg tablet
Composition : Rosuvastatin Calcium IP eq. to Rosuvastatin (as pellets) 20 mg. + Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg. Excipients q.s.
Composition : Rosuvastatin (5mg) tablet
Composition : Rosuvastatin 5mg + fenofibrate 160 mg tablet
Composition : Rosuvastatin 20 mg + fenofibrate 160 mg tablet
Composition : Rosuvastatin 10mg + Clopidogrel 75mg Capsule
Composition : Rosuvastatin 10 mg + Ezetimibe 10 mg tablet
Composition : Rosuvastatin 20mg + Clopidogrel 75mg Tablet
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Moxonidine Tablets have strong demand in the cardiology and antihypertensive segment, making them a valuable specialty product for pharma distributors, wholesalers, and franchise partners. It is widely prescribed for essential hypertension and long-term blood pressure control, ensuring consistent prescription-driven demand.
Medical distributors and agencies benefit from the growing prevalence of hypertension and cardiovascular disorders. Effective in managing high blood pressure (hypertension) Acts on the central nervous system to help regulate blood pressure Suitable for patients requiring additional blood pressure control alongside other antihypertensive therapies Commonly prescribed by cardiologists and general physicians Supports long-term cardiovascular risk reduction Strong demand in hospital, clinic, and retail pharmacy segments Used in chronic hypertension management with regular follow-up care This makes it a specialty antihypertensive product with steady prescription demand.
Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Moxonidine 0.3 mg Tablets with monopoly rights, promotional support, quality manufacturing standards, attractive packaging, and competitive pricing for distributors and wholesalers.
Wholesalers and franchise partners benefit from consistent cardiology prescription demand, long-term patient therapy, strong physician confidence, and stable year-round turnover in the cardiovascular segment.
Interested distributors, stockists, and pharma franchise partners can contact Cafoli LifeCare Pvt Ltd to discuss monopoly territory rights, pricing structure, marketing support, and complete cardiology and antihypertensive product portfolio access to build a strong presence in the cardiovascular healthcare market.